

The last day of trading with the warrants of series T05 in Lumito AB is today, June 4, 2024

Today, June 4, 2024, is the last day of trading with the warrants of series T05 in Lumito AB (publ) ("Lumito" or the "Company"). The exercise period for the warrants runs up to and including June 10, 2024. Each warrant of series T05 gives the owner the right to subscribe for one (1) new share in the Company for a subscription price of SEK 0.75 per share.

Summarised terms for the warrants of series T05:

Exercise period: May 27, 2024 – June 10, 2024.

Subscription price: SEK 0.75 per share.

Issue volume: 34,406,248 warrants of series T05 entitles to subscription of 34,406,248 shares. If all warrants are exercised the Company will receive approximately SEK 25.8 million before issuing costs.

Last day for trading with warrants: June 4, 2024.

Share capital and dilution: If all warrants of series T05 are exercised the number of shares will increase with 34,406,248 shares from 206,437,488 shares to 240,843,736 shares and the share capital will increase with SEK 860,156.20, from SEK 5,160,937.20 to SEK 6,021,093.40, corresponding to a maximal dilution effect of 14.3 percent if the number of shares.

Note that the warrants that are not exercised at the latest June 10, 2024, or sold at the latest June 4, 2024, will expire without value. For the warrants of series T05 not to lose their value, the holder must actively subscribe for new shares or sell the warrants. Please note that some nominees may close registration earlier than June 10, 2024.

Advisers

Mangold Fondkommission AB is financial adviser and Advokatfirman Lindahl KB is legal advisor to Lumito in connection with the exercise of the warrants of series T05.

For further information, please contact:

Mattias Lundin, CEO Lumito

E-mail: ml@lumito.se

Ph: +46 76 868 45 09

Lumito

Lumito specialises in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalised healthcare. The technology enables higher-contrast images without irrelevant background information, making it easier for pathologists to find cancer indications. The technology, based on Up Converting NanoParticles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shortened analysis times. The method has several potential applications, but Lumito has focused primarily on digital pathology and first on a release of SCIZYS by Lumito for use in research laboratories. The company is a spin-off of a research group at the Department of Atomic Physics and Laser Centre. www.lumito.se/en

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

Attachments

[The last day of trading with the warrants of series T05 in Lumito AB is today, June 4, 2024](#)